Apricus Biosciences, Inc.
20.08.2012 15:42
---------------------------------------------------------------------------
SAN DIEGO, 2012-08-20 15:42 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) (www.apricusbio.com)
today announced a podium presentation entitled, 'Nine months treatment with
alprostadil cream (Vitaros(r)) results in sustained improvement of erectile
function in males suffering from erectile dysfunction,' will take place on
Tuesday, August 28, 2012, at 2:30 p.m. CT as part of the upcoming World Meeting
on Sexual Medicine ('WMSM'), which will take place in Chicago, IL, on August
26-30, 2012. The presentation will discuss the results of a subpopulation
analysis of an open label dose titration efficacy and safety study to support
Vitaros(r) at the dose of 300 mcg in 100 mg of cream.
This is the second Apricus Bio abstract accepted by the WMSM for presentation
at this key medical industry meeting. On August 16, 2012, Apricus Bio announced
that its abstract related to Femprox(r), its drug candidate in development for
female sexual arousal disorder ('FSAD'), had also been accepted as a podium
presentation.
The Vitaros(r) (alprostadil 0.3% topical cream) data will be presented by Dr.
Jacques Buvat, director of the Centre d'Etude et de Traitement de la Pathologie
de l'Appareil Reproducteur et de la Psychosomatique (CETPARP) and a member of
Apricus Bio's Vitaros(r) Clinical Advisory Board. Dr. Buvat is also a member of
editorial boards for the International Journal of Impotence Research, Archivio
Italiano Nephrologia Andrologia, Andrologie and Gynecologie Obstetrique
Fertilite, chief editor of bulletins for the International Society for Sexual
and Impotence Research and the French Societe de Medecine de la Reproduction,
president of the Association pour l'Etude et le Traitement de la Pathologie de
l'Appareil Reproducteur et de la Psychomatique, and of the Association pour le
Developpement de l'Information et de la Recherche sur la Sexualite (ADIRS). He
has written more than 300 scientific papers.
About Vitaros(r)
Vitaros(r) is a topically delivered formulation of alprostadil delivered with
Dodecyl 2-N, N-(dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus'
proprietary NexACT(r) delivery technology, for the treatment of erectile
dysfunction ('ED'). When absorbed through the skin, alprostadil, a vasodilator,
directly boosts blood flow, thereby causing an erection.
Vitaros(r) differs from oral medications in two ways. First, it is applied
locally, directly to the penis as a cream, instead of taken orally and absorbed
systemically. This topical application helps to reduce side effects and
provides men who cannot take the existing oral medications a patient-friendly
alternative. Second, clinical studies have shown that patients on average had
successful sexual intercourse starting 5 minutes from the allocation of the
Vitaros(r), compared to a reported onset time of 30 minutes, or longer, for oral
medications.
About Apricus Biosciences, Inc.
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets
innovative treatments that help large patient populations across numerous,
high-demand therapeutic classes. The Company has four approved products and has
developed a strong pipeline of multiple late-stage product opportunities. With
commercial operations in both the U.S. and Europe (France), Apricus Bio
generates revenues and growth from sales of its commercial products and by
out-licensing, in certain territories, its pipeline products and NexACT(r)
technology.
Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Abbot Laboratories, Sandoz, Warner Chilcott, Wockhardt, and Bracco, and
co-promotes multiple products in France.
Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on
the NASDAQ under the ticker symbol APRI.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its products and
product candidates, to have its products such as Vitaros(r) and product
candidates receive patent protection and be approved by relevant regulatory
authorities, to successfully commercialize such products as Vitaros(r) and
NexACT(r) product candidates and drug delivery technology and to achieve its
development, commercialization and financial goals. Readers are cautioned not
to place undue reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company's most
recent annual report on Form 10-K, subsequent quarterly reports filed on Form
10-Q and other filings made with the SEC. Copies of these reports are available
from the SEC's website or without charge from the Company.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
News Source: NASDAQ OMX
20.08.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences Announces Podium Presentation of Vitaros(R) Clinical Data at 2012 World Meeting on Sexual Medicine
| Source: EQS Group AG